Homeopathy in Cuban epidemic neuropathy: an open clinical trial

Br Homeopath J. 2001 Jul;90(3):154-7. doi: 10.1054/homp.1999.0481.

Abstract

In an outbreak of epidemic neuropathy (EN) in Cuba (1992-1993), most patients were improved by vitamin therapy. In subjects with residual symptoms, alternative treatments including homeopathy were suggested to ameliorate optic and peripheral signs of the disease. An open clinical pilot trial was conducted on 31 patients with long standing symptoms of optic (OPTI group, n=15) or peripheral EN (PERI group, n=16). During the trial, OPTI and PERI patients continued the same treatment that they received before. Carboneum sulphuratum and Tabacum in homeopathic dilutions were administered for 30 days. These medicines are specific to optic EN, but not closely linked with peripheral EN. Clinical status was evaluated by neurological and ophthalmologic tests at diagnosis (Ddiag), 7 days before homeopathic treatment (D0) and 90 days after (D90). From D0 to D90, the percentages of improvement were 73.3% for the OPTI form and 12.5% for the PERI form. The percentage of improved OPTI patients was significantly higher after the homeopathic treatment vs the period between Ddiag and D0 for optical EN (P<0.01), but not for PERI subjects (P>0.05). In the OPTI group, colour vision, visual acuity and visual field improved after homeopathic treatment (P<0.001), these parameters did not change between Ddiag and D90 (P>0.05). Carboneum sulphuratum and Tabacum showed a reasonable effectiveness in optical EN, but were not effective in PERI EN.

Publication types

  • Clinical Trial

MeSH terms

  • Cuba / epidemiology
  • Disease Outbreaks
  • Female
  • Humans
  • Male
  • Materia Medica / therapeutic use*
  • Optic Neuritis / drug therapy*
  • Optic Neuritis / epidemiology*
  • Optic Neuritis / etiology
  • Peripheral Nervous System Diseases / drug therapy*
  • Peripheral Nervous System Diseases / epidemiology*
  • Peripheral Nervous System Diseases / etiology
  • Pilot Projects
  • Treatment Outcome

Substances

  • Materia Medica